Drug General Information |
Drug ID |
D0Y0LQ
|
Former ID |
DNC013964
|
Drug Name |
N-((1H-indol-2-yl)methyl)-2-phenylethanamine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H18N2
|
Canonical SMILES |
C1=CC=C(C=C1)CCNCC2=CC3=CC=CC=C3N2
|
InChI |
1S/C17H18N2/c1-2-6-14(7-3-1)10-11-18-13-16-12-15-8-4-5-9-17(15)19-16/h1-9,12,18-19H,10-11,13H2
|
InChIKey |
LMNUEZRZRYCQSM-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Amine oxidase [flavin-containing] A |
Target Info |
Inhibitor |
[1]
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
Dopamine degradation
|
Putrescine degradation III
|
Noradrenaline and adrenaline degradation
|
Serotonin degradation
|
Superpathway of melatonin degradation
|
Melatonin degradation II
|
KEGG Pathway
|
Glycine, serine and threonine metabolism
|
Arginine and proline metabolism
|
Histidine metabolism
|
Tyrosine metabolism
|
Phenylalanine metabolism
|
Tryptophan metabolism
|
Drug metabolism - cytochrome P450
|
Metabolic pathways
|
Serotonergic synapse
|
Dopaminergic synapse
|
Cocaine addiction
|
Amphetamine addiction
|
Alcoholism
|
NetPath Pathway
|
IL4 Signaling Pathway
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
5-Hydroxytryptamine degredation
|
Dopamine receptor mediated signaling pathway
|
PathWhiz Pathway
|
Histidine Metabolism
|
Tyrosine Metabolism
|
Glycine and Serine Metabolism
|
Reactome
|
Norepinephrine Neurotransmitter Release Cycle
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Biogenic Amine Synthesis
|
Oxidative Stress
|
Dopamine metabolism
|
Phase 1 - Functionalization of compounds
|
Neurotransmitter Release Cycle
|
Neurotransmitter Clearance In The Synaptic Cleft
|
Serotonin Transporter Activity
|
References |
REF 1 | Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. Epub 2008 Oct 2.Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. |